Navigation Links
Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
Date:8/19/2007

uted earnings per share were $0.05 in the second quarter of 2006. During the quarter, Skystar recognized non-cash interest expenses related to the debenture interest payment and warrants totaling $622,730. The company did not incur these expenses in the second quarter of 2006.

Adjusting net income to exclude non-cash debt financing and other expenses related to the Company's debenture interest payment and warrants, non-GAAP net income for the second quarter of 2007 was up 59.5% to $771,041 from $483,343 in the second quarter of 2006. Adjusted non-GAAP profit margin was 22.8% compared to 17.5% in the same quarter a year ago. Adjusted non-GAAP fully diluted earnings per share were $0.04 compared to fully diluted earnings per share of $0.05 in the second quarter of 2006.

Six Month Results

Revenues for the first half of 2007 were $4.7 million, up 26% from $3.8 million during the first half of 2006. Gross profit was $2.6 million, or 56% of revenues, up 52% from $1.7 million, or 46% of revenues, in the first half of 2006. Operating income was $1.1 million, or 23% of revenues, up 31% from $829,916, or 22% of sales, in the first half of 2006. Net loss for the first half of 2007 was $222,409, or ($0.26) per diluted share, compared to net income of $637,235, or $0.07 per diluted share, in the same period a year ago. Fully diluted earnings per share for the first six months reflect the one-time non-cash conversion expense of the convertible debentures. Adjusting net income to exclude non-cash debt financing and other expenses related to the Company's convertible debentures and warrants of $755,524, non-GAAP net income was $533,116 million, or $0.03 per fully diluted share, in the first six months of 2007.

Financial Condition

As of June 30, 2007, Skystar Bio-Pharmaceutical had $2.9 million in cash and restricted cash, total liabilities of $2.8 million and working capital of $3.9 million. Shareholders' equity increased to $15.0 million from $9.7 mil
'/>"/>

SOURCE Skystar Bio-Pharmaceutical Co.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... May 28, 2015 ... the addition of Jain PharmaBiotech,s new report  ... Companies"  to their offering.       ... a challenge in management. With nearly 8 ... seven major markets of the world and ...
(Date:5/28/2015)... 27, 2015 Research and Markets( http://www.researchandmarkets.com/research/l9dqwt/animal_genetics ) ... Market by Products, by Testing services - Global Forecast ... The global animal genetics market is estimated to be ... a CAGR of 8-9% during the forecast period of ... driven by increasing animal protein consumption, increasing adoption of ...
(Date:5/28/2015)... 28, 2015 Natera, Inc., a leader ... published in Ultrasound in Obstetrics & Gynecology ... non-invasive prenatal test (NIPT) can identify a complete ... A study based upon data collected in ... in about 1 in 1,000 pregnancies, although other ...
(Date:5/28/2015)... 28, 2015 Biscayne Pharmaceuticals, Inc ., ... its growth hormone-releasing hormone (GHRH) technology will be discussed in ... Annual Meeting. The data show that the family of ... blockers, is present on many primary breast cancer cells ... GHRH antagonists could have broad anti-cancer potential in breast ...
Breaking Biology Technology:Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 3Global Animal Genetics (Canine, Equine, Poultry, Porcine, Bovine, and Genetic Material) Market 2015 - Global Forecast to 2020 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 3Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3
... JOSEPH, Mich., Feb. 5 GeneGo, Inc., the ... has extended their,licensing agreement with GeneGo and have ... Bioinformatics, R&D and clinical studies,with global access to ... for functional analysis of biological OMICs data,featuring a ...
... Forest Laboratories, Inc.,(NYSE: FRX ) ... III study of,memantine HCl (currently marketed as ... novel once-daily formulation. The study evaluated,the efficacy, ... 28 mg,memantine extended-release, once-daily formulation compared to ...
... Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS), a biotechnology Company ... targeting the chronic inflammation,underlying cardiovascular and neurological disease, ... present a Company Overview at BIO,CEO & Investor ... at 11:00,a.m. (ET) on Tuesday, February 12, 2008. ...
Cached Biology Technology:GSK Extends GeneGo License and Adds New Products 2Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation 2Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation 3Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation 4Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel 2Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel 3
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/13/2015)... , April 13, 2015 ... Research, "Global Biometrics Market Forecast & Opportunities, 2020", the ... CAGR of around 14% till 2020. The biometrics ... large scale implementation and review of biometric management ... of new products with greater efficiency, are resulting ...
(Date:4/10/2015)... 2015 Research and Markets ( ... "Security Competitive Profiles - NEC" report to their ... NEC will continue to supply a range of IT ... a company focus on the development of a Big ... opportunities in the Asia-Pacific region ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... Immunogenetics experts at The Children,s Hospital of Philadelphia ... characterize the genes that encode HLA molecules. The ... technology to type human leukocyte antigens (HLAs)--complex, highly ... to immune function. The new test may ...
... will be the subject of a symposium on Saturday, February 15, ... Advancement of Science in Chicago. The session, which features two ... Martin Chalfie, will take place 10:00-11:30 a.m. CST in Grand Ballroom ... the first 2014 winner of the Golden Goose Award ...
... aware of the health benefits of dietary fiber. But what ... Research at the University of Michigan Medical School, the University ... Sweden, has begun to uncover how our gut bacteria metabolize ... Trillions of bacteria live in human intestines - there are ...
Cached Biology News:CHOP introduces HLA typing by next-generation sequencing to its clinical services 2CHOP introduces HLA typing by next-generation sequencing to its clinical services 3U-M scientists & colleagues investigate the fiber of our being 2
BD BioCoat Gelatin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of gelatin....
... an internal standard for the quantification of ... 5-OxoETE is a polyunsaturated keto acid formed ... neutrophils. It stimulates cytosolic calcium levels in ... 5-OxoETE selectively stimulates the migration and degranulation ...
...
... The dsRNA Marker consists of ten double-stranded ... 300, 400, 500 and 1,000 base pairs. ... marker for determinating sizes of double-stranded RNAs. ... the dsRNA Marker is adjusted to approximately ...
Biology Products: